 | • レポートコード：MRC2-11QY07578 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は髄芽腫医薬品のグローバル市場について調査・分析したレポートです。種類別（ジアンヒドロガラクチトール、IMP-5471、イピリムマブ、インドキシモド、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別髄芽腫医薬品の競争状況、市場シェア ・世界の髄芽腫医薬品市場：種類別市場規模 2015年-2020年（ジアンヒドロガラクチトール、IMP-5471、イピリムマブ、インドキシモド、その他） ・世界の髄芽腫医薬品市場：種類別市場規模予測 2021年-2026年（ジアンヒドロガラクチトール、IMP-5471、イピリムマブ、インドキシモド、その他） ・世界の髄芽腫医薬品市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の髄芽腫医薬品市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の髄芽腫医薬品市場分析：米国、カナダ ・ヨーロッパの髄芽腫医薬品市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの髄芽腫医薬品市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の髄芽腫医薬品市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの髄芽腫医薬品市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bayer AG、Bristol-Myers Squibb Company、DelMar Pharmaceuticals Inc、Ignyta Inc、IMPACT Therapeutics Inc、Lipocure Ltd、MacroGenics Inc、NewLink Genetics Corp、Novogen Ltd、Ono Pharmaceutical Co Ltd、Progenics Pharmaceuticals Inc、Stemline Therapeutics Inc、ThromboGenics NV、VBI Vaccines Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Medulloblastoma Drug Market
The global Medulloblastoma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Medulloblastoma Drug Scope and Market Size
Medulloblastoma Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Medulloblastoma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Medulloblastoma Drug market is segmented into
Dianhydrogalactitol
IMP-5471
Ipilimumab
Indoximod
Others
Segment by Application, the Medulloblastoma Drug market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Medulloblastoma Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Medulloblastoma Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Medulloblastoma Drug Market Share Analysis
Medulloblastoma Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Medulloblastoma Drug business, the date to enter into the Medulloblastoma Drug market, Medulloblastoma Drug product introduction, recent developments, etc.
The major vendors covered:
Bayer AG
Bristol-Myers Squibb Company
DelMar Pharmaceuticals Inc
Ignyta Inc
IMPACT Therapeutics Inc
Lipocure Ltd
MacroGenics Inc
NewLink Genetics Corp
Novogen Ltd
Ono Pharmaceutical Co Ltd
Progenics Pharmaceuticals Inc
Stemline Therapeutics Inc
ThromboGenics NV
VBI Vaccines Inc
1 Study Coverage
1.1 Medulloblastoma Drug Product Introduction
1.2 Market Segments
1.3 Key Medulloblastoma Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Medulloblastoma Drug Market Size Growth Rate by Type
1.4.2 Dianhydrogalactitol
1.4.3 IMP-5471
1.4.4 Ipilimumab
1.4.5 Indoximod
1.4.6 Others
1.5 Market by Application
1.5.1 Global Medulloblastoma Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Medulloblastoma Drug Market Size, Estimates and Forecasts
2.1.1 Global Medulloblastoma Drug Revenue 2015-2026
2.1.2 Global Medulloblastoma Drug Sales 2015-2026
2.2 Global Medulloblastoma Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Medulloblastoma Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Medulloblastoma Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Medulloblastoma Drug Competitor Landscape by Players
3.1 Medulloblastoma Drug Sales by Manufacturers
3.1.1 Medulloblastoma Drug Sales by Manufacturers (2015-2020)
3.1.2 Medulloblastoma Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Medulloblastoma Drug Revenue by Manufacturers
3.2.1 Medulloblastoma Drug Revenue by Manufacturers (2015-2020)
3.2.2 Medulloblastoma Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Medulloblastoma Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Medulloblastoma Drug Revenue in 2019
3.2.5 Global Medulloblastoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Medulloblastoma Drug Price by Manufacturers
3.4 Medulloblastoma Drug Manufacturing Base Distribution, Product Types
3.4.1 Medulloblastoma Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Medulloblastoma Drug Product Type
3.4.3 Date of International Manufacturers Enter into Medulloblastoma Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Medulloblastoma Drug Market Size by Type (2015-2020)
4.1.1 Global Medulloblastoma Drug Sales by Type (2015-2020)
4.1.2 Global Medulloblastoma Drug Revenue by Type (2015-2020)
4.1.3 Medulloblastoma Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Medulloblastoma Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Medulloblastoma Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Medulloblastoma Drug Revenue Forecast by Type (2021-2026)
4.2.3 Medulloblastoma Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Medulloblastoma Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Medulloblastoma Drug Market Size by Application (2015-2020)
5.1.1 Global Medulloblastoma Drug Sales by Application (2015-2020)
5.1.2 Global Medulloblastoma Drug Revenue by Application (2015-2020)
5.1.3 Medulloblastoma Drug Price by Application (2015-2020)
5.2 Medulloblastoma Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Medulloblastoma Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Medulloblastoma Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Medulloblastoma Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Medulloblastoma Drug by Country
6.1.1 North America Medulloblastoma Drug Sales by Country
6.1.2 North America Medulloblastoma Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Medulloblastoma Drug Market Facts & Figures by Type
6.3 North America Medulloblastoma Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Medulloblastoma Drug by Country
7.1.1 Europe Medulloblastoma Drug Sales by Country
7.1.2 Europe Medulloblastoma Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Medulloblastoma Drug Market Facts & Figures by Type
7.3 Europe Medulloblastoma Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Medulloblastoma Drug by Region
8.1.1 Asia Pacific Medulloblastoma Drug Sales by Region
8.1.2 Asia Pacific Medulloblastoma Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Medulloblastoma Drug Market Facts & Figures by Type
8.3 Asia Pacific Medulloblastoma Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Medulloblastoma Drug by Country
9.1.1 Latin America Medulloblastoma Drug Sales by Country
9.1.2 Latin America Medulloblastoma Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Medulloblastoma Drug Market Facts & Figures by Type
9.3 Central & South America Medulloblastoma Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Medulloblastoma Drug by Country
10.1.1 Middle East and Africa Medulloblastoma Drug Sales by Country
10.1.2 Middle East and Africa Medulloblastoma Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Medulloblastoma Drug Market Facts & Figures by Type
10.3 Middle East and Africa Medulloblastoma Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Bayer AG
11.1.1 Bayer AG Corporation Information
11.1.2 Bayer AG Description and Business Overview
11.1.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bayer AG Medulloblastoma Drug Products Offered
11.1.5 Bayer AG Related Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Corporation Information
11.2.2 Bristol-Myers Squibb Company Description and Business Overview
11.2.3 Bristol-Myers Squibb Company Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bristol-Myers Squibb Company Medulloblastoma Drug Products Offered
11.2.5 Bristol-Myers Squibb Company Related Developments
11.3 DelMar Pharmaceuticals Inc
11.3.1 DelMar Pharmaceuticals Inc Corporation Information
11.3.2 DelMar Pharmaceuticals Inc Description and Business Overview
11.3.3 DelMar Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 DelMar Pharmaceuticals Inc Medulloblastoma Drug Products Offered
11.3.5 DelMar Pharmaceuticals Inc Related Developments
11.4 Ignyta Inc
11.4.1 Ignyta Inc Corporation Information
11.4.2 Ignyta Inc Description and Business Overview
11.4.3 Ignyta Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Ignyta Inc Medulloblastoma Drug Products Offered
11.4.5 Ignyta Inc Related Developments
11.5 IMPACT Therapeutics Inc
11.5.1 IMPACT Therapeutics Inc Corporation Information
11.5.2 IMPACT Therapeutics Inc Description and Business Overview
11.5.3 IMPACT Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 IMPACT Therapeutics Inc Medulloblastoma Drug Products Offered
11.5.5 IMPACT Therapeutics Inc Related Developments
11.6 Lipocure Ltd
11.6.1 Lipocure Ltd Corporation Information
11.6.2 Lipocure Ltd Description and Business Overview
11.6.3 Lipocure Ltd Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Lipocure Ltd Medulloblastoma Drug Products Offered
11.6.5 Lipocure Ltd Related Developments
11.7 MacroGenics Inc
11.7.1 MacroGenics Inc Corporation Information
11.7.2 MacroGenics Inc Description and Business Overview
11.7.3 MacroGenics Inc Sales, Revenue and Gross Margin (2015-2020)
11.7.4 MacroGenics Inc Medulloblastoma Drug Products Offered
11.7.5 MacroGenics Inc Related Developments
11.8 NewLink Genetics Corp
11.8.1 NewLink Genetics Corp Corporation Information
11.8.2 NewLink Genetics Corp Description and Business Overview
11.8.3 NewLink Genetics Corp Sales, Revenue and Gross Margin (2015-2020)
11.8.4 NewLink Genetics Corp Medulloblastoma Drug Products Offered
11.8.5 NewLink Genetics Corp Related Developments
11.9 Novogen Ltd
11.9.1 Novogen Ltd Corporation Information
11.9.2 Novogen Ltd Description and Business Overview
11.9.3 Novogen Ltd Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Novogen Ltd Medulloblastoma Drug Products Offered
11.9.5 Novogen Ltd Related Developments
11.10 Ono Pharmaceutical Co Ltd
11.10.1 Ono Pharmaceutical Co Ltd Corporation Information
11.10.2 Ono Pharmaceutical Co Ltd Description and Business Overview
11.10.3 Ono Pharmaceutical Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Ono Pharmaceutical Co Ltd Medulloblastoma Drug Products Offered
11.10.5 Ono Pharmaceutical Co Ltd Related Developments
11.1 Bayer AG
11.1.1 Bayer AG Corporation Information
11.1.2 Bayer AG Description and Business Overview
11.1.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bayer AG Medulloblastoma Drug Products Offered
11.1.5 Bayer AG Related Developments
11.12 Stemline Therapeutics Inc
11.12.1 Stemline Therapeutics Inc Corporation Information
11.12.2 Stemline Therapeutics Inc Description and Business Overview
11.12.3 Stemline Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Stemline Therapeutics Inc Products Offered
11.12.5 Stemline Therapeutics Inc Related Developments
11.13 ThromboGenics NV
11.13.1 ThromboGenics NV Corporation Information
11.13.2 ThromboGenics NV Description and Business Overview
11.13.3 ThromboGenics NV Sales, Revenue and Gross Margin (2015-2020)
11.13.4 ThromboGenics NV Products Offered
11.13.5 ThromboGenics NV Related Developments
11.14 VBI Vaccines Inc
11.14.1 VBI Vaccines Inc Corporation Information
11.14.2 VBI Vaccines Inc Description and Business Overview
11.14.3 VBI Vaccines Inc Sales, Revenue and Gross Margin (2015-2020)
11.14.4 VBI Vaccines Inc Products Offered
11.14.5 VBI Vaccines Inc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Medulloblastoma Drug Market Estimates and Projections by Region
12.1.1 Global Medulloblastoma Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Medulloblastoma Drug Revenue Forecast by Regions 2021-2026
12.2 North America Medulloblastoma Drug Market Size Forecast (2021-2026)
12.2.1 North America: Medulloblastoma Drug Sales Forecast (2021-2026)
12.2.2 North America: Medulloblastoma Drug Revenue Forecast (2021-2026)
12.2.3 North America: Medulloblastoma Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Medulloblastoma Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Medulloblastoma Drug Sales Forecast (2021-2026)
12.3.2 Europe: Medulloblastoma Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Medulloblastoma Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Medulloblastoma Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Medulloblastoma Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Medulloblastoma Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Medulloblastoma Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Medulloblastoma Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Medulloblastoma Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Medulloblastoma Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Medulloblastoma Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Medulloblastoma Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Medulloblastoma Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Medulloblastoma Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Medulloblastoma Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Medulloblastoma Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Medulloblastoma Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Medulloblastoma Drug Market Segments
Table 2. Ranking of Global Top Medulloblastoma Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Medulloblastoma Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Dianhydrogalactitol
Table 5. Major Manufacturers of IMP-5471
Table 6. Major Manufacturers of Ipilimumab
Table 7. Major Manufacturers of Indoximod
Table 8. Major Manufacturers of Others
Table 9. Global Medulloblastoma Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Medulloblastoma Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Medulloblastoma Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Medulloblastoma Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Medulloblastoma Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Medulloblastoma Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Medulloblastoma Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Medulloblastoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Medulloblastoma Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Medulloblastoma Drug as of 2019)
Table 18. Medulloblastoma Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Medulloblastoma Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Medulloblastoma Drug Price (2015-2020) (USD/Pcs)
Table 21. Medulloblastoma Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Medulloblastoma Drug Product Type
Table 23. Date of International Manufacturers Enter into Medulloblastoma Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Medulloblastoma Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Medulloblastoma Drug Sales Share by Type (2015-2020)
Table 27. Global Medulloblastoma Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Medulloblastoma Drug Revenue Share by Type (2015-2020)
Table 29. Medulloblastoma Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Medulloblastoma Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Medulloblastoma Drug Sales Share by Application (2015-2020)
Table 32. North America Medulloblastoma Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Medulloblastoma Drug Sales Market Share by Country (2015-2020)
Table 34. North America Medulloblastoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Medulloblastoma Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Medulloblastoma Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Medulloblastoma Drug Sales Market Share by Type (2015-2020)
Table 38. North America Medulloblastoma Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Medulloblastoma Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Medulloblastoma Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Medulloblastoma Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Medulloblastoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Medulloblastoma Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Medulloblastoma Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Medulloblastoma Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Medulloblastoma Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Medulloblastoma Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Medulloblastoma Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Medulloblastoma Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Medulloblastoma Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Medulloblastoma Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Medulloblastoma Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Medulloblastoma Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Medulloblastoma Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Medulloblastoma Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Medulloblastoma Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Medulloblastoma Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Medulloblastoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Medulloblastoma Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Medulloblastoma Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Medulloblastoma Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Medulloblastoma Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Medulloblastoma Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Medulloblastoma Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Medulloblastoma Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Medulloblastoma Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Medulloblastoma Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Medulloblastoma Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Medulloblastoma Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Medulloblastoma Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Medulloblastoma Drug Sales Market Share by Application (2015-2020)
Table 72. Bayer AG Corporation Information
Table 73. Bayer AG Description and Major Businesses
Table 74. Bayer AG Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Bayer AG Product
Table 76. Bayer AG Recent Development
Table 77. Bristol-Myers Squibb Company Corporation Information
Table 78. Bristol-Myers Squibb Company Description and Major Businesses
Table 79. Bristol-Myers Squibb Company Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Bristol-Myers Squibb Company Product
Table 81. Bristol-Myers Squibb Company Recent Development
Table 82. DelMar Pharmaceuticals Inc Corporation Information
Table 83. DelMar Pharmaceuticals Inc Description and Major Businesses
Table 84. DelMar Pharmaceuticals Inc Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. DelMar Pharmaceuticals Inc Product
Table 86. DelMar Pharmaceuticals Inc Recent Development
Table 87. Ignyta Inc Corporation Information
Table 88. Ignyta Inc Description and Major Businesses
Table 89. Ignyta Inc Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Ignyta Inc Product
Table 91. Ignyta Inc Recent Development
Table 92. IMPACT Therapeutics Inc Corporation Information
Table 93. IMPACT Therapeutics Inc Description and Major Businesses
Table 94. IMPACT Therapeutics Inc Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. IMPACT Therapeutics Inc Product
Table 96. IMPACT Therapeutics Inc Recent Development
Table 97. Lipocure Ltd Corporation Information
Table 98. Lipocure Ltd Description and Major Businesses
Table 99. Lipocure Ltd Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Lipocure Ltd Product
Table 101. Lipocure Ltd Recent Development
Table 102. MacroGenics Inc Corporation Information
Table 103. MacroGenics Inc Description and Major Businesses
Table 104. MacroGenics Inc Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. MacroGenics Inc Product
Table 106. MacroGenics Inc Recent Development
Table 107. NewLink Genetics Corp Corporation Information
Table 108. NewLink Genetics Corp Description and Major Businesses
Table 109. NewLink Genetics Corp Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. NewLink Genetics Corp Product
Table 111. NewLink Genetics Corp Recent Development
Table 112. Novogen Ltd Corporation Information
Table 113. Novogen Ltd Description and Major Businesses
Table 114. Novogen Ltd Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. Novogen Ltd Product
Table 116. Novogen Ltd Recent Development
Table 117. Ono Pharmaceutical Co Ltd Corporation Information
Table 118. Ono Pharmaceutical Co Ltd Description and Major Businesses
Table 119. Ono Pharmaceutical Co Ltd Medulloblastoma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 120. Ono Pharmaceutical Co Ltd Product
Table 121. Ono Pharmaceutical Co Ltd Recent Development
Table 122. Progenics Pharmaceuticals Inc Corporation Information
Table 123. Progenics Pharmaceuticals Inc Description and Major Businesses
Table 124. Progenics Pharmaceuticals Inc Medulloblastoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 125. Progenics Pharmaceuticals Inc Product
Table 126. Progenics Pharmaceuticals Inc Recent Development
Table 127. Stemline Therapeutics Inc Corporation Information
Table 128. Stemline Therapeutics Inc Description and Major Businesses
Table 129. Stemline Therapeutics Inc Medulloblastoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 130. Stemline Therapeutics Inc Product
Table 131. Stemline Therapeutics Inc Recent Development
Table 132. ThromboGenics NV Corporation Information
Table 133. ThromboGenics NV Description and Major Businesses
Table 134. ThromboGenics NV Medulloblastoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 135. ThromboGenics NV Product
Table 136. ThromboGenics NV Recent Development
Table 137. VBI Vaccines Inc Corporation Information
Table 138. VBI Vaccines Inc Description and Major Businesses
Table 139. VBI Vaccines Inc Medulloblastoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 140. VBI Vaccines Inc Product
Table 141. VBI Vaccines Inc Recent Development
Table 142. Global Medulloblastoma Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 143. Global Medulloblastoma Drug Sales Market Share Forecast by Regions (2021-2026)
Table 144. Global Medulloblastoma Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 145. Global Medulloblastoma Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 146. North America: Medulloblastoma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 147. North America: Medulloblastoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 148. Europe: Medulloblastoma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 149. Europe: Medulloblastoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 150. Asia Pacific: Medulloblastoma Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 151. Asia Pacific: Medulloblastoma Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 152. Latin America: Medulloblastoma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 153. Latin America: Medulloblastoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 154. Middle East and Africa: Medulloblastoma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 155. Middle East and Africa: Medulloblastoma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 156. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 157. Key Challenges
Table 158. Market Risks
Table 159. Main Points Interviewed from Key Medulloblastoma Drug Players
Table 160. Medulloblastoma Drug Customers List
Table 161. Medulloblastoma Drug Distributors List
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources
List of Figures
Figure 1. Medulloblastoma Drug Product Picture
Figure 2. Global Medulloblastoma Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Dianhydrogalactitol Product Picture
Figure 4. IMP-5471 Product Picture
Figure 5. Ipilimumab Product Picture
Figure 6. Indoximod Product Picture
Figure 7. Others Product Picture
Figure 8. Global Medulloblastoma Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Medulloblastoma Drug Report Years Considered
Figure 13. Global Medulloblastoma Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Medulloblastoma Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Medulloblastoma Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Medulloblastoma Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Medulloblastoma Drug Sales Market Share by Region in 2019
Figure 18. Global Medulloblastoma Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Medulloblastoma Drug Revenue Market Share by Region in 2019
Figure 20. Global Medulloblastoma Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Medulloblastoma Drug Revenue in 2019
Figure 22. Medulloblastoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Medulloblastoma Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Medulloblastoma Drug Sales Market Share by Type in 2019
Figure 25. Global Medulloblastoma Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Medulloblastoma Drug Revenue Market Share by Type in 2019
Figure 27. Global Medulloblastoma Drug Market Share by Price Range (2015-2020)
Figure 28. Global Medulloblastoma Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Medulloblastoma Drug Sales Market Share by Application in 2019
Figure 30. Global Medulloblastoma Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Medulloblastoma Drug Revenue Market Share by Application in 2019
Figure 32. North America Medulloblastoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Medulloblastoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Medulloblastoma Drug Sales Market Share by Country in 2019
Figure 35. North America Medulloblastoma Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Medulloblastoma Drug Market Share by Type in 2019
Figure 41. North America Medulloblastoma Drug Market Share by Application in 2019
Figure 42. Europe Medulloblastoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Medulloblastoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Medulloblastoma Drug Sales Market Share by Country in 2019
Figure 45. Europe Medulloblastoma Drug Revenue Market Share by Country in 2019
Figure 46. Germany Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Medulloblastoma Drug Market Share by Type in 2019
Figure 57. Europe Medulloblastoma Drug Market Share by Application in 2019
Figure 58. Asia Pacific Medulloblastoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Medulloblastoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Medulloblastoma Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Medulloblastoma Drug Revenue Market Share by Region in 2019
Figure 62. China Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Medulloblastoma Drug Market Share by Type in 2019
Figure 85. Asia Pacific Medulloblastoma Drug Market Share by Application in 2019
Figure 86. Latin America Medulloblastoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Medulloblastoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Medulloblastoma Drug Sales Market Share by Country in 2019
Figure 89. Latin America Medulloblastoma Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Medulloblastoma Drug Market Share by Type in 2019
Figure 97. Latin America Medulloblastoma Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Medulloblastoma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Medulloblastoma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Medulloblastoma Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Medulloblastoma Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Medulloblastoma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Medulloblastoma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Medulloblastoma Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Medulloblastoma Drug Market Share by Application in 2019
Figure 110. North America Medulloblastoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Medulloblastoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Medulloblastoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Medulloblastoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Medulloblastoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Medulloblastoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Medulloblastoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Medulloblastoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Medulloblastoma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Medulloblastoma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…- 大麻薬の世界市場（～2026年） Drugs with chemicals taken directly from the marijuana plant，or with synthetic versions of chemicals naturally found in marijuana. Market Analysis and Insights: Global Cannabis Drug Market The global Cannabis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…
- 乱用薬物検査サービスの世界市場（～2026年） Drug of Abuse Testing Services is the use of testing services to avoid the negative effects of drug abuse, to reduce the accidents. In addition to rise in number of substance abusers and increase in number of government initiatives to avoid ill effects of substance abuse at workplace & reduce number…
- 薬物スクリーニング検査サービスの世界市場（～2026年） Market Analysis and Insights: Global Drug Screening Laboratory Service Market The global Drug Screening Laboratory Service market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high da…
- 子宮内膜ポリープ治療薬の世界市場（～2026年） Uterine polyps are common gynecological diseases. Broadly speaking, it refers to all tumors attached to the uterine wall by slender pedicle. Mostly benign. Market Analysis and Insights: Global Uterine Polyps Drug Market The global Uterine Polyps Drug market size is projected to reach US$ XX million …